Galectin Therapeutics Appoints Renowned Neurosurgeon-Scientist Dr. Henry Brem to Board
GALT has more than doubled off its 52-week low of $1.12.
Summary
Galectin Therapeutics Inc. has appointed Dr. Henry Brem, an internationally recognized neurosurgeon-scientist from Johns Hopkins, to its Board of Directors, enhancing its scientific and clinical expertise.
Key Events · Executive and Board Changes · GALT
-
New Board Member Appointed
Dr. Henry Brem was appointed as a member of the Board of Directors, effective March 12, 2026.
-
Enhanced Scientific Expertise
Dr. Brem is an internationally recognized neurosurgeon-scientist and leader in translational medicine, bringing deep experience in clinical development and novel therapeutic platforms.
-
Distinguished Academic Background
He serves as the Henry Brem Professor of Neurosurgery at Johns Hopkins University, is Co-Director of the Brain Cancer Program at the Sidney Kimmel Comprehensive Cancer Center, and is a member of the National Academy of Medicine.
-
Relevant Industry Experience
His work includes developing image-guided surgical techniques and localized drug delivery systems, directly aligning with the company's focus on developing therapeutics for chronic liver disease and cancer.
Analysis · GALT · Life Sciences
Galectin Therapeutics has significantly strengthened its Board of Directors with the appointment of Dr. Henry Brem. Dr. Brem's extensive background as an internationally recognized neurosurgeon-scientist, including his leadership roles at Johns Hopkins University and his pioneering work in translational medicine and localized drug delivery systems, brings invaluable scientific and clinical expertise. This appointment is particularly relevant for Galectin Therapeutics as it advances its lead drug belapectin for MASH cirrhosis and explores other oncology programs, providing enhanced strategic guidance and credibility to its development efforts.
At the time of this filing, GALT was trading at $3.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $205M. The 52-week trading range was $1.12 to $7.13. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.